This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Bayer's Ac-PSMA-Trillium Phase I Success
Tech Clinical trial results

Bayer's Ac-PSMA-Trillium Phase I Success

Analysis based on 7 articles · First reported Feb 27, 2026 · Last updated Feb 27, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive Phase I clinical trial results for Bayer's Ac-PSMA-Trillium (BAY 3563254) are expected to have a positive impact on Bayer's stock and its standing in the pharmaceutical market, particularly in the precision oncology sector. This advancement offers hope for new treatment options for patients with metastatic castration-resistant prostate cancer, a condition with high unmet medical need.

Pharmaceuticals Biotechnology Healthcare
Event Summary

Bayer announced positive results from its global Phase I PAnTHa study (NCT06217822) for Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy for advanced metastatic castration-resistant prostate cancer (mCRPC). The study successfully identified the dose for expansion, with over 80% of patients achieving a PSA50 response. The data, presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, showed no dose-limiting toxicities or treatment-related deaths, with common adverse events being dry mouth, fatigue, and nausea. This supports advancing Ac-PSMA-Trillium to the next phase of clinical development, reinforcing Bayer's strategic focus on precision oncology and prostate cancer treatment. The drug originated from Bayer's 2021 acquisitions of Bayer===PSMA Therapeutics and Bayer===Noria Therapeutics.

Key Actions
100 Bayer announced positive Phase I clinical trial results for Ac-PSMA-Trillium
40 Bayer acquired Bayer===PSMA Therapeutics and Bayer===Noria Therapeutics Bayer===PSMA Therapeutics
40 Bayer acquired Bayer===PSMA Therapeutics and Bayer===Noria Therapeutics Bayer===Noria Therapeutics
Entities Involved
stock
Bayer
Bayer announced positive Phase I clinical trial results for its next-generation targeted alpha therapy, Ac-PSMA-Trillium (BAY 3563254), for metastatic castration-resistant prostate cancer. This successful identification of the expansion dose and promising efficacy data support advancing the therapy to the next phase of clinical development, potentially boosting Bayer's position in precision oncology.
Importance 100 Sentiment 70
per
Dominik Ruettinger
Dominik Ruettinger, Head of Research and Early Development for Oncology at Bayer's Pharmaceuticals Division, expressed excitement about the Phase I PAnTHa study results, highlighting Bayer's continued focus on prostate cancer treatment and personalized healthcare solutions.
Importance 30 Sentiment 50
per
Fred Saad
Fred Saad, Professor and Chairman of Surgery at the University of Montreal, commented on the urgent need for new precision therapies for metastatic castration-resistant prostate cancer and supported further investigation of Ac-PSMA-Trillium.
Importance 20 Sentiment 50
subs
Bayer===PSMA Therapeutics
PSMA-Trillium, the drug under investigation, resulted from the acquisition of Bayer===PSMA Therapeutics by Bayer in 2021.
Importance 10 Sentiment 50
subs
Bayer===Noria Therapeutics
PSMA-Trillium, the drug under investigation, resulted from the acquisition of Bayer===Noria Therapeutics by Bayer in 2021.
Importance 10 Sentiment 50
cnt
United States
The American Society of Clinical Oncology Genitourinary Cancers Symposium, where the data was presented, took place in San Francisco, California, United States.
Importance 5 Sentiment 0
cnt
Canada
Fred Saad, a key opinion leader quoted in the article, is associated with the University of Montreal in Canada.
Importance 5 Sentiment 0
Relationships
Dominik Ruettinger related ↔ Bayer
Bayer===PSMA Therapeutics related ↔ Bayer
Bayer===Noria Therapeutics related ↔ Bayer
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.